New experimental immunotherapy benefits people with cancer of the bladder urothelial Advanced -
First advance potential treatment method for "forgotten killer" metastatic cancer bladder, in almost 30 years shown to benefit people with bladder cancer metastatic urothelial
new MPDL3280A experimental immunotherapy has been shown to shrink tumors in 43% of people (13/30) who had been treated for cancer of advanced urothelial bladder (UBC) with a specific tumor type (PD-L1 positive). It is thought that PD-L1 plays a role in suppressing the immune system in patients MPDL3280A and is designed to make the cancer cells more vulnerable to the immune system of the body. The results of this Phase I trial are particularly important as metastatic bladder cancer - dubbed the "forgotten killer" - is an area of high unmet demand for which there were no new developments in methods treatment for almost 30 years. In 2011, there were 5,081 deaths from bladder cancer in the UK.
A complete response (disappearance of visible tumors on scans) was demonstrated in 7% of patients (2/30). The results show that Grade 3 (severe) adverse events related to treatment (AEs) occurred in 4% (3/68) of those in the study and there were no life-threatening or fatal (grade 4-5) adverse treatment related. Roche is developing a companion test immunohistochemistry (IHC) to help identify people who are most likely to respond to MPDL3280A, which will be validated in the pivotal trials. The results of the study are presented as a last minute abstract by lead researcher Professor Thomas Powles, Barts Cancer Institute at Queen Mary University of London at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago .
"We are excited by these early results of the scene show promising results for patients with advanced urothelial bladder cancer," said Professor Thomas Powles at Medicine Center Cancer Research Experimental UK on cancer of the Barts cancer Institute and Barts Health NHS Trust, "bladder cancer is the seventh most common cancer in the UK and there have been no new treatment options for over 30 years. It is therefore imperative that we continue to discuss emerging therapeutic options, particularly in the advanced forms of the disease where outlook for patients is particularly low. "
Approximately 10,400 people are diagnosed with bladder cancer each year in the UK, making it the seventh most common cancer overall and the fourth most common cancer in men. cancer of advanced bladder can be particularly difficult to treat and the outlook is poor for patients compared those who were diagnosed early. a study recently published in the Journal of Clinical Urology found that the survival of bladder cancer is deteriorating in England. Despite the number of new cases of bladder cancer decreasing, the number of deaths has not reduced by a similar proportion, and is currently higher than other European countries, with similar incidence rates.
Approximately 0% of bladder cancers in UK are urothelial which means they have developed in the cells of the lining of the bladder (urothelium). Because they line the bladder, these cells come into contact with the waste in the urine that can cause cancer.
EmoticonEmoticon